Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has not progressed after platinum-based chemoradiotherapy (CRT) [1]. It offers a new treatment option that has been shown to improve the survival of patients with this aggressive form of lung cancer.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Pain and autism
Hurdles to pain treatment for autistic patients
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal